Neutralizing Antibody MarketSize and Trends
The global neutralizing antibody market size was valued at US$ 190.44 billion in 2023 and is projected to reach US$ 338.86 billion by 2030 at a compound annual growth rate (CAGR) of 8.6% from 2023 to 2030. The rising prevalence of infectious diseases, increasing research and development activities, and growing demand for personalized medicine are the key factors driving the growth of the market.
Neutralizing Antibody Market Trends
- Increasing Focus on COVID-19 Treatment and Prevention: The COVID-19 pandemic continues to drive significant demand for neutralizing antibodies. Monoclonal antibody therapies, such as Regeneron, one of the leading biotechnology company’s casirivimab/imdevimab and Eli Lilly and Company, one of the global leading b pharmaceutical company’s bamlanivimab/etesevimab, have received emergency use authorizations or approvals for the treatment and prevention of COVID-19. The ongoing research and development of neutralizing antibodies targeting SARS-CoV-2 variants reflect the industry's focus on combating the pandemic.
- Development of Multi-Specific and Bispecific Antibodies: Multi-specific and bispecific antibodies are gaining attention in the neutralizing antibody market. These antibodies are designed to simultaneously target multiple antigens or receptors, offering enhanced therapeutic effects and increased specificity. The demand for enhanced treatment results and the ability to tackle intricate diseases is propelling the advancement of multi-specific and bispecific neutralizing antibodies.
- Advancements in Antibody Engineering and Design: Antibody engineering and design techniques continue to advance, enabling the generation of optimized neutralizing antibodies. Methods such as antibody humanization, affinity maturation, and Fc (antibodies) engineering are used to enhance antibody efficacy, half-life, and safety profiles. The incorporation of novel platforms, including antibody fragments and antibody-drug conjugates, further expands the possibilities for therapeutic development.
- Shift Towards Subcutaneous Administration: Traditionally, neutralizing antibodies have been administered intravenously, requiring hospital or clinic visits. However, there is a growing trend towards subcutaneous administration, enabling self-administration or administration in outpatient settings. This shift improves patient convenience, reduces healthcare burden, and increases accessibility to neutralizing antibody therapies.
U.S.: 
U.K. : 
India : 
